This is the authors' abstract. We don't add key points for this paper.
Pharmacologic treatments, cell-based therapies, and other technology-driven interventions will likely play a combinatorial role in the evolving management of SCI as the field continues to evolve.
No takes yet. Share an insight, caveat, or question.
Hachem et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: